Status:
ACTIVE_NOT_RECRUITING
BIOTIPRA: BIOmarker-guided Treatment Decisions in Psoriatic and Rheumatoid Arthritis
Lead Sponsor:
University of Manchester
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
TNFi drugs remain the most prescribed first-line biologics for patients with rheumatoid arthritis (RA). However, up to 40% of RA patients fail to respond to TNFi treatment. One explanation of non-resp...
Eligibility Criteria
Inclusion
- Patients with RA about to start therapy with adalimumab or certolizumab
- Age 18 and over, male or female
- Willing to take part in the study
- Patients who consent to take part in the BRAGGSS study
Exclusion
- Patients unwilling or unable to take part in the study
- Pregnant women or nursing (breast feeding) mothers.
- Planned pregnancy within next 12 months.
- Scheduled surgery in the next 12 months or other pre-planned reasons for treatment discontinuation in the next 12 months.
- Contraindication to adalimumab or certolizumab according to the summary of product characteristics
Key Trial Info
Start Date :
May 31 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03853395
Start Date
May 31 2019
End Date
July 1 2027
Last Update
January 17 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Musculoskeletal Research
Manchester, England, United Kingdom, M13 9PT
2
Hampshire Hospitals NHS Foundation Trust
Basingstoke, Hampshire, United Kingdom, RG24 9NA
3
Midlands Partnership NHS Foundation Trust
Stafford, Staffordshire, United Kingdom, ST16 3AG
4
Leicester Royal Infirmary
Leicester, United Kingdom, LE1 5WW